Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 6/2009

01.06.2009 | Original Article

Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma

verfasst von: Patrick Veit-Haibach, Florian M. Vogt, Robert Jablonka, Hilmar Kuehl, Andreas Bockisch, Thomas Beyer, Gerlinde Dahmen, Sandra Rosenbaum, Gerald Antoch

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 6/2009

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the diagnostic accuracy of contrast-enhanced FDG-PET/CT (ce-PET/CT), PET-only, and CT-only in patients with newly diagnosed and resected cutaneous malignant melanoma.

Methods

A final group of 56 patients (mean age 62 years, range 23–86 years; 29 women, 27 men) were staged with ce-PET/CT after resection of the primary tumour. Histopathology as well as clinical follow-up (mean 780 days, range 102–1,390 days) served as the standards of reference. Differences between the staging modalities were tested for statistical significance with McNemar’s test.

Results

All imaging procedures provided low sensitivities in the detection of lymph nodes (sensitivity N-stage: PET/CT and PET-only 38.5%; CT-only 23.1%) and distant metastases (sensitivity M-stage: PET/CT 41.7%, PET-only 33.3%, CT-only 25.0%) in initial staging after resection of the primary tumour. No statistically significant differences were detected between the imaging procedures (p > 0.05). PET/CT resulted in an alteration in further treatment in two patients compared to PET-only and in four patients compared to CT-only.

Conclusion

All imaging modalities had a low sensitivity on initial staging of patients with malignant melanoma. Thus, close patient follow-up must be considered mandatory.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57 1:43–6.PubMedCrossRef Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57 1:43–6.PubMedCrossRef
2.
Zurück zum Zitat Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19 16:3622–34.PubMed Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19 16:3622–34.PubMed
3.
Zurück zum Zitat Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of surgery Nov 1970;172 5:902–8. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Annals of surgery Nov 1970;172 5:902–8.
4.
Zurück zum Zitat Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19 16:3635–48.PubMed Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19 16:3635–48.PubMed
5.
Zurück zum Zitat Day CL Jr, Sober AJ, Lew RA, Mihm MC Jr, Fitzpatrick TB, Kopf AW, et al. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 1981;47 5:955–62.PubMedCrossRef Day CL Jr, Sober AJ, Lew RA, Mihm MC Jr, Fitzpatrick TB, Kopf AW, et al. Malignant melanoma patients with positive nodes and relatively good prognoses: microstaging retains prognostic significance in clinical stage I melanoma patients with metastases to regional nodes. Cancer 1981;47 5:955–62.PubMedCrossRef
7.
Zurück zum Zitat Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351 10:998–1012.PubMedCrossRef Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351 10:998–1012.PubMedCrossRef
8.
Zurück zum Zitat Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004;34 4:242–53.PubMedCrossRef Friedman KP, Wahl RL. Clinical use of positron emission tomography in the management of cutaneous melanoma. Semin Nucl Med 2004;34 4:242–53.PubMedCrossRef
9.
Zurück zum Zitat Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42 5 Suppl:1S–93S.PubMed Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42 5 Suppl:1S–93S.PubMed
10.
Zurück zum Zitat Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24 7:1178–87.PubMedCrossRef Reinhardt MJ, Joe AY, Jaeger U, Huber A, Matthies A, Bucerius J, et al. Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients. J Clin Oncol 2006;24 7:1178–87.PubMedCrossRef
11.
Zurück zum Zitat Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007;244 2:566–74.PubMedCrossRef Strobel K, Dummer R, Husarik DB, Perez Lago M, Hany TF, Steinert HC. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 2007;244 2:566–74.PubMedCrossRef
12.
Zurück zum Zitat Strobel K, Skalsky J, Steinert HC, Dummer R, Hany TF, Bhure U, et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 2007;215 3:192–201.PubMedCrossRef Strobel K, Skalsky J, Steinert HC, Dummer R, Hany TF, Bhure U, et al. S-100B and FDG-PET/CT in therapy response assessment of melanoma patients. Dermatology 2007;215 3:192–201.PubMedCrossRef
13.
Zurück zum Zitat Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002;179 6:1555–60.PubMed Antoch G, Freudenberg LS, Stattaus J, Jentzen W, Mueller SP, Debatin JF, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR Am J Roentgenol 2002;179 6:1555–60.PubMed
14.
Zurück zum Zitat Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003;30 4:588–96.PubMed Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003;30 4:588–96.PubMed
15.
Zurück zum Zitat Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133 5:510–5.PubMedCrossRef Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133 5:510–5.PubMedCrossRef
16.
Zurück zum Zitat Valk PE, Bailey DL, Townsend DW, Maisey MN. Positron emission tomography: basic science and clinical practice. Berlin: Springer; 2003. Valk PE, Bailey DL, Townsend DW, Maisey MN. Positron emission tomography: basic science and clinical practice. Berlin: Springer; 2003.
17.
Zurück zum Zitat American Joint Committee on Cancer. Cancer staging manual. 6th edition. Heidelberg: Springer; 2002. American Joint Committee on Cancer. Cancer staging manual. 6th edition. Heidelberg: Springer; 2002.
19.
Zurück zum Zitat Tango T. Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 1998;17 8:891–908.PubMedCrossRef Tango T. Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 1998;17 8:891–908.PubMedCrossRef
20.
Zurück zum Zitat Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45 8:1323–7.PubMed Fuster D, Chiang S, Johnson G, Schuchter LM, Zhuang H, Alavi A. Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med 2004;45 8:1323–7.PubMed
21.
Zurück zum Zitat Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41 9:1491–4.PubMed Crippa F, Leutner M, Belli F, Gallino F, Greco M, Pilotti S, et al. Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma. J Nucl Med 2000;41 9:1491–4.PubMed
22.
Zurück zum Zitat Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82 9:1664–71.PubMedCrossRef Rinne D, Baum RP, Hor G, Kaufmann R. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients. Cancer 1998;82 9:1664–71.PubMedCrossRef
23.
Zurück zum Zitat Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77 4:237–42.PubMedCrossRef Wagner JD, Schauwecker DS, Davidson D, Wenck S, Jung SH, Hutchins G. FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume. J Surg Oncol 2001;77 4:237–42.PubMedCrossRef
24.
Zurück zum Zitat Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000;89 5:1019–25.PubMedCrossRef Tyler DS, Onaitis M, Kherani A, Hata A, Nicholson E, Keogan M, et al. Positron emission tomography scanning in malignant melanoma. Cancer 2000;89 5:1019–25.PubMedCrossRef
25.
Zurück zum Zitat Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104 3:570–9.PubMedCrossRef Wagner JD, Schauwecker D, Davidson D, Logan T, Coleman JJ 3rd, Hutchins G, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer 2005;104 3:570–9.PubMedCrossRef
26.
Zurück zum Zitat Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004;45 Suppl 1:72S–81S.PubMed Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med 2004;45 Suppl 1:72S–81S.PubMed
27.
Zurück zum Zitat Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002;7 4:271–8.PubMedCrossRef Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist 2002;7 4:271–8.PubMedCrossRef
28.
Zurück zum Zitat Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003;29 8:662–4.PubMedCrossRef Havenga K, Cobben DC, Oyen WJ, Nienhuijs S, Hoekstra HJ, Ruers TJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol 2003;29 8:662–4.PubMedCrossRef
29.
Zurück zum Zitat Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16 5:1770–6.PubMed Macfarlane DJ, Sondak V, Johnson T, Wahl RL. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma. J Clin Oncol 1998;16 5:1770–6.PubMed
30.
Zurück zum Zitat Wagner JD, Schauwecker D, Davidson D, Coleman JJ 3rd, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17 5:1508–15.PubMed Wagner JD, Schauwecker D, Davidson D, Coleman JJ 3rd, Saxman S, Hutchins G, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol 1999;17 5:1508–15.PubMed
Metadaten
Titel
Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma
verfasst von
Patrick Veit-Haibach
Florian M. Vogt
Robert Jablonka
Hilmar Kuehl
Andreas Bockisch
Thomas Beyer
Gerlinde Dahmen
Sandra Rosenbaum
Gerald Antoch
Publikationsdatum
01.06.2009
Verlag
Springer-Verlag
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 6/2009
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-008-1049-x

Weitere Artikel der Ausgabe 6/2009

European Journal of Nuclear Medicine and Molecular Imaging 6/2009 Zur Ausgabe